参考文献 [1] Ajello L, Georg L K, Steigbigel R T, et al. A case of phaeohyphomycosis caused by a new species of Phialophora.[J]. Mycologia,1974,66(3):490-498. [2] Revankar S G. Therapy of infections caused by dematiaceous fungi.[J]. Expert Rev Anti Infect Ther,2005,3(4):601-612. [3] Laniado-Laborin R, Cabrales-Vargas M N. Amphotericin B: side effects and toxicity.[J]. Rev Iberoam Micol,2009, 26(4):223-227. [4] Denning D W. Echinocandin antifungal drugs.[J]. Lancet,2003,362(9390):1142-1151. [5] Li D M, de Hoog G S. Cerebral phaeohyphomycosis--a cure at what lengths?[J]. Lancet Infect Dis,2009,9(6):376-383. [6] Revankar S G, Patterson J E, Sutton D A, et al. Disseminated phaeohyphomycosis: review of an emerging mycosis.[J]. Clin Infect Dis,2002,34(4):467-476. [7] National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts----second edition. Approved standard M27-A2. NCCLS, Wayne, PA, USA. 2002. [8] Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.[J]. J Clin Microbiol,2001,39(3):954-958. [9] Mcginnis M R. Chromoblastomycosis and phaeohyphomycosis: new concepts, diagnosis, and mycology.[J]. J Am Acad Dermatol,1983,8(1):1-16. [10] Rossmann S N, Cernoch P L, Davis J R. Dematiaceous fungi are an increasing cause of human disease.[J]. Clin Infect Dis,1996,22(1):73-80. [11] Oztas E, Odemis B, Kekilli M, et al. Systemic Phaeohyphomycosis Caused by Exophiala dermatitidis Resembling Primary Sclerosing Cholangitis.[J]. J Med Microbiol,2009,58(9):1243-1246 [12] Alabaz D, Kibar F, Arikan S, et al. Systemic phaeohyphomycosis due to Exophiala (Wangiella) in an immunocompetent child.[J]. Med Mycol,2009, 47(6):653-657 [13] Chang X, Li R, Yu J, et al. Phaeohyphomycosis of the central nervous system caused by Exophiala dermatitidis in a 3-year-old immunocompetent host.[J]. J Child Neurol,2009,24(3):342-345. [14] Filizzola M J, Martinez F, Rauf S J. Phaeohyphomycosis of the central nervous system in immunocompetent hosts: report of a case and review of the literature.[J]. Int J Infect Dis,2003,7(4):282-286. [15] Krishnan-Natesan S. Terbinafine: a pharmacological and clinical review.[J]. Expert Opin Pharmacother,2009,10(16):2723-2733. [16] Hope W W, Billaud E M, Lestner J, et al. Therapeutic drug monitoring for triazoles.[J]. Curr Opin Infect Dis,2008,21(6):580-586. [17] Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients.[J]. Clin Infect Dis,2003,37(5):728-732. |